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Abstract15
This work is a proof of concept study establishing the potential of electrosprayed Janus particles for16
combined photodynamic therapy-chemotherapy. Sub-micron sized particles of polyvinylpyrrolidone17
containing either an anti-cancer drug (carmofur) or a photosensitiser (rose bengal; RB), and Janus18
particles containing both in separate compartments were prepared. The functional components were19
present in the amorphous form in all the particles, and infrared spectroscopy indicated that20
intermolecular interactions formed between the different species. In vitro drug release studies21
showed that both carmofur and RB were released at approximately the same rate, with dissolution22
complete after around 250 min. Cytotoxicity studies were undertaken on model human dermal23
fibroblasts (HDF) and lung cancer (A549) cells, and the influence of light on cell death explored.24
Formulations containing carmofur as the sole active ingredient were highly toxic to both cell lines,25
with or without a light treatment. The RB formulations were non-toxic to HDF when no light was26
applied, and with photo-treatment caused large amounts of cell death for both A549 and HDF cells.27
The Janus formulation containing both RB and carmofur was non-toxic to HDF without light, and only28
slightly toxic with the photo-treatment. In contrast it was hugely toxic to A549 cells when light was29
applied. The Janus particles are thus highly selective for cancer cells, and it is hence proposed that30
such electrosprayed particles containing both a chemotherapeutic agent and photosensitiser have31
great potential in combined chemotherapy/photodynamic therapy.32
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Introduction36
Photodynamic therapy (PDT) is a FDA (Food and Drug Administration) approved treatment for non-37
small cell lung cancer and esophageal cancer (1). It involves the application of a photosensitizer, an38
agent that generates cytotoxic reactive oxygen species (ROS) upon excitation with visible or near39
infrared light. Owing to the requirement for light-activation, PDT is a highly selective method which40
can be used to deliver a therapeutic dose localised only at the irradiated areas, and thus cancerous41
tissue can be treated without damaging healthy cells. In addition, the phototoxicity produced by PDT42
does not affect the collagen or elastin of the tissue and thus allows localised destruction of cancer43
cells with no long-term scarring or side effects (2).44
More recently, the combination of anticancer drugs with photosensitisers in a single formulation has45
been explored as an aggressive means to synergise ROS-mediated cancer cell necrosis with the46
apoptotic events driven by chemotherapeutic agents (3-5). Although combinatorial photo-47
chemotherapeutic protocols have been successfully employed, and some are at pre-clinical stages (6,48
7), there are still significant formulation challenges that need to be overcome: namely, the drug carrier49
must be capable of being co-loaded with two or more different compounds (i.e. the photosensitizer50
and the drug) which often exhibit completely different physicochemical properties (e.g. lipophilicity,51
molecular mass). Furthermore, the formulation should reach the target sites and release the52
molecular cargo at the desired tissue sites or cellular organelles with release profiles optimised to53
maximise the therapeutic effect (8). In order to fulfil these requirements, it is critical to develop new54
formulation methods capable of providing architectural compartmentalisation at the nano- to55
microscale in order to produce systems able to act as single platforms for multiple drug compounds56
in combinatorial cancer photo-chemo-therapies (9). The Kataoka group have established the57
importance of such compartmentalisation in micellar formulations with a core-shell architecture,58
and elegantly demonstrated the protection of active biologics (DNA/RNA) from photo-oxidative59
damage during photochemical internalization (10, 11).60
Janus particles are anisotropic “two-faced” particles with different surface features on the two sides61
(12). Such nano- or micro-scale formulations constitute an alternative design approach for the co-62
delivery of multiple APIs. They offer some potential benefits over core/shell materials, because in63
the Janus architecture both compartments are exposed to the external environment. This means64
that, for instance, particles could be fabricated with the two sides made of different polymers. A65
particle could thus be taken up by a cell and release the drug loading from each of the two sides at66
different rates or times. Alternatively, one side of the particle could selectively bind to a cell67
membrane while the other delivers a drug payload.68
The synthesis and fabrication of Janus particles has proved to be challenging (13). Although there are69
several methods which can be used to produce these particles, such as the self-assembly of block70
copolymers, lithography based masking/unmasking, phase separation, and controlled surface71
nucleation, these methods are often multiple-step, time-consuming, and difficult if not impossible to72
scale up (14). An attractive alternative route to Janus systems is electrodynamic atomisation (EHDA).73
This is a top-down and one-step process which can produce a wide range of micro- or nanostructures,74
using electrical energy. Typically, a polymer and functional component(s) (such as active75
pharmaceutical ingredients) are dissolved in a volatile solvent, which is then loaded into a syringe76
fitted with a metal tip (the spinneret). The solution is expelled from the syringe at a controlled rate77
towards a metal collector, and a large (kV) potential difference is applied between the two. This causes78
rapid evaporation of the solvent as the polymer solution travels towards the collector, and leads to79
micron-sized particles (electrospraying) or nanofibers (electrospinning), typically with the functional80
component amorphously distributed in the polymer matrix.81
Most often, single-fluid EHDA is used to make monolithic fibres or particles (15, 16). However, by using82
a side-by-side spinneret – essentially two metal needle tips adjacent to one another and touching in83
the middle – it is possible to prepare Janus structures. Gupta and Wilkes first reported the fabrication84
of Janus fibers using side-by-side electrospinning with polyvinyl chloride/polyurethane and polyvinyl85
chloride)/polyvinylidiene fluoride in 2003 (17), but since then only a very limited number of additional86
studies have followed their initial work (18-21).87
The setup required to create side-by-side structures from the electrospraying technique has been88
investigated in several articles. For instance, the possibility of controlling the size of Janus particles89
from 135 µm to 3 µm by means of varying the electric field has been reported by Sun et al. (22). In90
another example, the large-scale production of Janus particles with adjustable morphologies and91
structures was achieved by using an oppositely charged twin-head electrospraying set-up (23). This92
permitted the creation of Janus particles from two different solutions ejected through two separate93
nozzles at high voltages of opposite polarities; the two streams collide with each other after solvent94
evaporation and precursor gelation, producing a range of different heterostructures.95
On the basis of the work described above, we hypothesised that Janus particles loaded with a96
chemotherapeutic drug and a photosensitiser may have great potential in PDT. To date, the use of97
Janus particles fabricated by EDHA techniques in photodynamic therapy has not been explored, and98
thus here we describe a proof of concept study in which we set out to demonstrate that it is possible99
to prepare such particles loaded with a model chemotherapeutic agent (carmofur, an antineoplastic100
agent, which can prevent, inhibit or halt tumour growth) and a photosensitiser (rose bengal, RB) in101
two different compartments. In order to rapidly assess the utility of our formulations, we opted to use102
the fast-dissolving polymer polyvinylpyrrolidone (PVP) as the carrier matrix. The chemical structures103
of all three materials are given in Figure 1. PVP/carmofur, PVP/rose bengal, and Janus104
PVP/carmofur/rose bengal particles were prepared and fully characterised. Drug release studies were105
undertaken, and finally in vitro cell experiments performed to explore the effect of the formulations106
on both non-cancer and cancerous cells.107
Experimental methods108
Materials109
Rose bengal (RB, 95% Dye) was purchased from Sigma-Aldrich, ethanol (96% v/v) from Fisher Scientific110
Ltd, and PVP (Mw 56 kDa) from Alfa Aesar. Carmofur (99%) was supplied by Cambridge Scientific.111
Phosphate buffered saline (PBS, pH 7.4) powder was obtained from Sigma-Aldrich.112
Electrospraying113
A 5 % w/v solution of PVP was prepared in ethanol and stirred until complete dissolution of the114
polymer had occurred. Additional solutions were also prepared consisting of 5 % w/v PVP and the115
desired amounts of RB and carmofur (see Table 1). The polymer solutions were then loaded into a 5116
mL syringe (Terumo) fitted with a spinneret of 0.61 mm internal diameter (Nordson EFD). Solutions117
were pumped at a flow rate of 0.5 mL h-1 using a syringe pump (KDS100, Cole Parmer). To prepare the118
Janus particles, a side-by-side spinneret comprising two 0.6 mm internal diameter spinnerets joined119
together was employed with two syringe pumps driving the fluids independently (both at a rate of 0.5120
mL h-1). A high voltage DC power supply (HCP 35-35000, FuG Elektronik) was used to apply a potential121
difference (15-17 kV; see Table 1) between the spinneret and a metal collector plate (30 x 20 cm)122
covered in aluminium foil placed 20 – 22 cm away (details are given in Table 1). Experiments were123
performed at temperatures of 24 – 27 °C and relative humidities in the range 36 – 39 %.124
Characterisation125
Scanning electron microscopy (SEM): The morphology of the materials produced was studied using a126
field emission scanning electron microscope (FEI Quanta 200F) connected to a secondary electron127
detector. Samples were adhered to an SEM stub with carbon-coated double-sided tape and sputter-128
coated with gold prior to measurement. The particle size distribution was determined from SEM129
micrographs, using the ImageJ software v1.48 (National Institutes of Health, US) to manually measure130
the diameters of at least 100 particles. The diameters of spherical particles were measured, and for131
elongated particles the shortest width was used to estimate their size.132
Fluorescence microscopy: An EVOS® FL Cell Imaging System (ThermoFisher Scientific) fitted with GFP133
and DAPI filters was used to acquire fluorescence microscopy images.134
Differential scanning calorimetry (DSC): Analysis was conducted using a Q2000 differential scanning135
calorimeter (DSC; TA Instruments). Approximately 2 – 5 mg of sample was placed inside a non-136
hermetically sealed aluminum pan (T130425, TA Instruments). DSC analysis was carried out from 0 -137
140 or 200 °C, at a temperature ramp of 10 °C min-1 under a 50 mL min-1 flow of oxygen-free nitrogen138
gas. Data analysis was carried out using the TA Universal Analysis software.139
X-ray diffraction (XRD) patterns were obtained using a Miniflex 600 (Rigaku) X-ray diffractometer140
supplied with Cu Kα radiation. Patterns were recorded over the 2Ө range 3 – 40° at a speed of 5° min-141
1. The generator voltage was set at 40 kV and the current at 15 mA.142
FT-IR spectroscopy: Fourier transform infrared spectroscopy was carried out using a Spectrum 100143
FTIR spectrometer (PerkinElmer) in the range 500 − 4000 cm−1, with a resolution of 4 cm-1 and144
accumulation of 16 scans.145
Functional performance assays146
Drug release was carried out in 250 mL of PBS (10 mM; pH 7.4) at a temperature of 37 °C. 10 mg of147
electrosprayed particles (PVP-RB, PVP-C, or PVP-RBC) were accurately weighed and placed in a capsule148
(Capsugel size 0, gelatine). The capsule was then placed in a sinker before being added to the149
dissolution medium. Experiments were conducted under continuous mechanical stirring at 100 rpm.150
Drug release was calculated on the basis of pre-determined calibration curves, obtained at151
wavelengths of 547 nm for rose bengal (24) and 259 nm for carmofur (25). PVP has no absorbance at152
these wavelengths, and the two active ingredients do not interfere with each other for quantification153
purposes.154
Cell viability: The human dermal fibroblast (HDF) cell line was purchased from Life Technologies (lot155
771555). The cells were maintained at 37 °C, under a 5% CO2 atmosphere in Dulbecco’s modified156
Eagle’s medium-high glucose (DMEM-HG) supplemented with 10 % (v/v) heat-inactivated foetal157
bovine serum (FBS), 2 mM L-glutamine (Life Technologies), 1 % MEM non-essential amino acids,158
gentamicin solution (100 μg mL-1) and amphotericin B solution (0.25 μg mL-1). Cells were passaged159
when a confluence of 70 – 80 % was reached. This process involved a treatment with 0.05 % trypsin-160
EDTA solution and reseeding at a concentration of 1.5 x 105 cells mL-1.161
The lung cancer cell line A549 (ATCC CCL-185) was a kind gift from Dr Satyanarayana Somavarapu (UCL162
School of Pharmacy). The cells were maintained at 37 °C in a 5% CO2 atmosphere in RPMI medium163
(Gibco) supplemented with penicillin (100 µg mL-1), streptomycin (100 µg mL-1), L-glutamine (2 mM),164
and 10 % (v/v) heat-inactivated FBS (Gibco). The cells were passaged every 3 days and reseeded prior165
to use at a concentration of 9 x 105 cells mL-1.166
For assessment of the formulations, the materials to be tested were first dissolved in complete DMEM-167
HG or RPMI medium as appropriate to form solutions at 1 mg mL-1. These were filtered through a 0.22168
µm filter, and cells were directly resuspended in 180 μL of each solution in a 96-well plate (Greiner 169 
Bio-One Cellstar). Cell densities were 7.5 x 104 cells mL-1 for HDF and 5.5 x 104 cells mL-1 for A549. Doses170
of carmofur and RB in the controls were matched to their concentrations in the single-fluid particle171
solutions.172
The cells were incubated with the dissolved formulations for 24 h, and then irradiated at 521 nm using173
a microscope illuminator (DiCon LED) for 20 min (1050 mW, 0.32 cm2). Control experiments were also174
performed in which the cells were not exposed to light. Cell viability was determined using the175
CellTiter-Glo™ luminescent cell viability assay (Promega). The luminescent reagent was prepared176
following the manufacturer’s instructions and added to the culture plates with a reagent volume equal177
to the volume of cell culture medium present in each well. After addition, the plate was left for 30 min178
at room temperature before luminescence was recorded using a SpectraMax M2e spectrophotometer179
(Molecular Devices). The viability of the cells was then calculated using the following formula:180
181
All experiments were performed in triplicate. Data from cell culture experiments are presented as182
mean ± standard deviation (S.D.) from three independent experiments, and were analysed using the183
SPSS Statistics Software. Statistical significance of differences was evaluated by one-way ANOVA using184
Games-Howell or Bonferroni post hoc tests. The level of significance was set at probabilities of p <185
0.001 (***) and p < 0.05 (*).186
Results187
Particle morphology188
SEM images of the particles prepared are given in Figure 2. The pure PVP particles have very regular189
spherical shapes, and the population is relatively monodisperse at 1.170 ± 0.162 µm. The addition of190
rose bengal to the formulation (PVP-RB) results in the production of some elongated particles, and a191
broadening of the size distribution (0.537 ± 0.461 µm). There are a large number of small particles at192
around 0.5 µm or below, with a smaller number of larger (> 1 µm) particles. The carmofur-containing193
(PVP-C) samples have more regular morphologies than PVP-RB, with the vast majority of the particles194
being spherical with smooth surfaces (Figure 2(c)). Only a few elongated particles can be observed,195
and the average diameter of the PVP-C particles is 0.497 ± 0.209 µm, similar to PVP-RB.196
Janus particles were then prepared from side-by-side electrospraying with carmofur in one197
compartment and rose bengal in the other. These particles have rather irregular morphologies, with198
average size of 0.607 ± 0.191 μm. A central join or dimple is visible at the interface of the two sides, 199 
reflecting the characteristic compartmentalised architecture of the particles (Figure 2(d)). The dual-200
compartment structure of the particles is also very clear from the fluorescence microscopy images201
(Figure 2(e)), where a distinct fluorescent signal is visible from each compartment corresponding202
either to rose bengal (green) or to carmofur (red); a yellow hue in the middle is also visible where the203
two signals overlap.204
Physical characterisation205
The physical form of RB and carmofur in the particles was assessed by XRD and DSC, and the results206
are shown in Figure 3. Pure carmofur exists as a crystalline material, as is evidenced by the presence207
of a clear melting endotherm at ca. 115°C in DSC (Figure 3(a)). The DSC thermogram also shows208
degradation peaks at T > 125 °C. The carmofur XRD pattern contains myriad Bragg reflections,209
confirming its crystalline nature. Rose bengal shows no melting events over the temperature range210
studied by DSC (its melting point is reported to be > 300 °C), but its crystalline nature is clear from the211
XRD pattern (Figure 3(b)).212
All the electrosprayed formulations are amorphous materials, with or without any functional213
component loaded. All the DSC thermograms show broad endotherms from approximately 40 – 130214
°C, attributed to the loss of adsorbed water (PVP is known to be highly hygroscopic), with no melting215
events present (Figure 3(a)). There are no Bragg reflections visible by XRD, with only the broad humps216
typical of amorphous systems being present in the diffraction patterns (Figure 3(b)). The absence of217
the carmofur melting endotherm in DSC and of the Bragg reflections from both carmofur and RB in218
the XRD patterns demonstrate that the active ingredients exist as amorphous solid dispersions in219
these formulations, as widely reported in the literature for electrosprayed systems (26).220
The interactions of RB and carmofur with the polymer were investigated by FT-IR spectroscopy. The221
spectra of the raw and fabricated materials are depicted in Figure 4. The spectra of the formulations222
appear to be a combination of the starting materials, and as expected, the major changes are observed223
in the carboxylate region of the spectrum. The C=O stretch of PVP is present at 1652 cm-1 , while rose224
bengal’s carbonyl stretch can be seen at 1614 cm-1; the shift of the carbonyl group to a lower225
wavenumber in rose bengal is a result of the higher electronegativity of the halogen substituents (27).226
With the PVP-RB particles, a single carbonyl band is found at 1652 cm-1. The PVP and rose bengal bands227
have thus merged, suggesting the presence of interactions (e.g. electrostatic forces) between the two228
components of the particles.229
Carmofur shows a series of peaks at 1660 – 1750 cm-1 and a broad peak at 1501 cm-1, which could all230
be attributable to C=O groups. The latter, together with a series of peaks between 1720 and 1750 cm-231
1, can still be discerned in the PVP-C particles, but the peaks at 1665 and 1688 cm-1 have merged with232
the PVP C=O stretch to give a single peak at around 1650 cm-1. The spectrum of the PVP-RBC particles233
looks very similar to the pure PVP data, presumably because of the small amounts of each drug present234
compared to the overall PVP content in the system. However, there is a distinctive broad peak from235
carmofur centred at 1735 cm-1 and the PVP C=O band is shifted to 1647 cm-1, again likely to be a result236
of intermolecular interactions.237
The phonon vibrations of the raw RB and carmofur materials are absent in all the electrosprayed238
particles, consistent with the lack of long-range order and amorphous physical form noted from XRD239
and DSC.240
Drug release241
Drug release profiles for the formulations are given in Figure 5. As expected for PVP-based systems,242
release occurs rapidly and plateaus after 250 min (ca. 4 h). This is rather slower than usually seen for243
PVP materials, which we ascribe to our use of a capsule as a container for the particles in these244
experiments. There is a significant burst release with > 25 % of the loaded drug being released within245
25 min. While the release profiles of RB are essentially identical from both the monolithic and Janus246
systems, the formation of Janus particles appears to reduce the release extent of carmofur: the profile247
of the release plots are very similar, but the PVP-C particles release 95.9 ± 6.6 % of the drug loading248
after 350 min while the PVP-RBC Janus particles release only 66.8 ± 9.9 % in the same time interval.249
RB, used here as its disodium salt, is highly soluble in water (1 mg mL-1), but carmofur is a poorly water-250
soluble drug (0.0273 mg mL-1). The in vitro release profiles of carmofur were thus much more251
influenced by the size and shape of the particles. Attempts were made to analyse the data using the252
Korsmeyer-Peppas model, but it was found that this model does not provide a good fit to the253
experimental data.254
Cytotoxicity studies255
The cytotoxicity of the particles was evaluated on the normal HDF cell line, and on A549 (lung cancer)256
cells (see Figure 6). When HDF cells are exposed to the particles without light exposure (Figure 6(a)),257
the viability of the cells treated with the PVP, PVP-RB and PVP-RBC particles is indistinguishable from258
the control of untreated cells. Cells treated with RB alone also show this high level of viability. As259
expected, the viability of cells treated with carmofur alone show significantly reduced viability (19.5 ±260
9.2 %). Those incubated with the PVP-C system have a cell viability of around 43.8 ± 17.9 %. When the261
same experiment is repeated but with the cells exposed to light at 521 nm (Figure 6(b)), very high262
levels of cell death are seen with RB or carmofur alone, and also with PVP-C. However, viability is much263
higher with the PVP-RB and PVP-RBC systems, at 92.3 ± 13.7 % and 72.4 ± 11.8 % respectively (as264
compared to 100 % for the untreated cells or 91.1 ± 12.3 % for PVP particles).265
The A549 cell line exhibits similar behaviour to the HDF cells in the absence of light. RB and PVP-RB266
lead to modest declines in viability, with values of 74.5 ± 15.1 % and 62.5 ± 8.2 % respectively. PVP-267
RBC gives viability very similar to pure PVP particles, at 83.9 ± 13.9 %. Incubation with carmofur or268
PVP-C results in virtually complete cell death (Figure 6(c)). The effect of light exposure was also269
explored on A459 cells (Figure 6(d)). The PVP and PVP-RB particles cause a moderate decline in270
viability, while RB alone reduces viability to ca. 30 %. Carmofur alone, PVP-C, and the Janus particles271
result in nearly quantitative cell death.272
From these experiments, it is clear that the PVP-RBC particles are effective in the selective killing of273
cancer cells. We calculated a selectivity index for the formulations, defined as the viability of HDF cells274
with light exposure divided by the viability of A549 cells under the same conditions (Table 2). From275
Table 2, it is clear that PVP has minimal toxicity for both HDF and A549 cells under these conditions,276
and carmofur has essentially the same toxicity with both cell lines, killing virtually all the cells present.277
The PVP-RB and PVP-C systems are more selective for cancer cells, while in the presence of light RB278
alone is much more toxic to HDF cells than A549. In contrast, the PVP-RBC Janus system shows a very279
high level of selectivity, being almost 1500 times as toxic to cancer cells as normal cells.280
Discussion281
The characterisation results demonstrate that side by side electrospraying could effectively be used282
to create bi-compartmentalized particles combining a photosensitizer (rose bengal) and a cytotoxic283
drug (carmofur). We successfully produced sub-micron sized particles with homogenously spherical284
morphologies and relatively narrow size distributions. The active components are present in the285
amorphous physical form in the formulations, as expected since the electrospraying technique induces286
rapid solvent evaporation, which prevents re recrystallization of the molecules (28). Our work adds287
to the body of literature on side-by-side EHDA processes. Similar setups have been used to create288
complex formulations that have been successful in co-loading incompatible drugs (29), allowing289
selective degradation of the compartments and controlled dual phase release kinetics (30), or long290
circulation nanocarriers, amongst others (31).291
In terms of their cellular activity, the PVP-RBC and PVP-RB materials did not show any significant292
decrease in HDF cell viability compared to the PVP control when no light irradiation was applied. This293
is expected, since light exposure is essential for the generation of cytotoxic ROS and inducing294
irreversible photodamage to cellular organelles, as reported in other studies (1, 32). The application295
of light increased the toxicity of PVP-RB somewhat, while the PVP-C material is toxic to these cells296
even without light. This is expected: carmofur is a prodrug and its active degradation product, 5-297
fluorouracil, has poor selectivity towards tumours (33). The Janus particles caused only small amounts298
of HDF cell death, with or without exposure to light.299
In the case of the experiments performed without light in the A549 cell line, a decrease of   ̴25 – 40 300
% cell viability was observed with the RB and PVP-RB formulations; this is expected to be caused by301
the intrinsic cytotoxicity of RB (even without exposure to light) (34). After light irradiation, PVP-RB302
causes very similar levels of cell death (ca. 30 %) as was observed with no light treatment. In303
contrast, PVP-C, and PVP-RBC kill almost all the cells present. The PVP-RBC formulation shows a very304
high level of selectivity for cancerous cells, inducing 1500-fold more cell death than with the non-305
cancerous HDF cells. This effect could be a result of the combination of photodynamic therapy and306
chemotherapy, which is proven to result in a significant inhibition of tumour proliferation, increased307
induction of apoptosis, and damage to tumour vasculature (35-37). Khadir et al. have also suggested308
that enhanced cytotoxicity could be correlated with improved intracellular and nuclear delivery of the309
two drugs (38). One of the key benefits of photodynamic therapy is its high selectivity for tumour310
cells due to the ability of the photosensitisers to accumulate in tumour tissue rather than in normal311
cells, further helping to improve the selectivity of PVP-RBC in this work (39).312
We thus demonstrate here that Janus particles prepared by electrospraying have great potential in313
combined photo-chemo-therapy, showing high selectivity for cancerous cells. For the purposes of314
proof-of-concept, the materials prepared in this work used PVP as the carrier. This polymer dissolves315
very rapidly upon addition to water, allowing rapid assessment of functional performance. Onward316
formulation will be required to develop practicable drug delivery systems, for instance by embedding317
the particles prepared here in a secondary polymer matrix, or by using alternative polymers to prepare318
the electrosprayed Janus particles. We will take the latter forward in our future work now that the319
concept of using such particles in photo-chemo-therapy has been proven.320
Conclusions321
The aim of this study was to develop a compartmentalized structure for combined photodynamic322
(PDT) and chemotherapeutic treatment of cancer. Electrospraying was used to generate sub-micron323
particles of polyvinylpyrrolidone containing either an anti-cancer drug (carmofur) or a photosensitiser324
for PDT (rose Bengal; RB), and also Janus structures containing both in separate compartments. The325
products were largely spherical particles, and in the Janus case two distinct sections can be seen. The326
functional components are present in the amorphous form, as demonstrated by X-ray diffraction and327
differential scanning calorimetry. IR spectroscopy indicated the presence of intermolecular328
interactions between the different components of the particles. Drug release from the formulations329
was rapid, reaching a maximum after around 250 min. In vitro cytotoxicity assays were performed in330
HDF and A549 cells. Formulations containing only RB as the active ingredient were non-toxic in the331
absence of light, but when light was provided proved similarly toxic to the normal HDF and cancerous332
A549 cells. Those containing carmofur were highly toxic to both cells lines regardless of the presence333
of light. The Janus formulations were non-toxic to HDF cells without light, and somewhat more toxic334
after light was provided. They caused the death of almost 100 % of the A549 cells after exposure to335
light, however. The Janus formulations are highly selective for cancerous cells, and thus336
electrosprayed Janus particles are expected to have great potential in photo-chemo-therapy.337
Acknowledgements338
This work was supported by the China National Science Foundation / UK Royal Society cost share339
international exchanges scheme (No. 51411130128/IE131748) and the National Science Foundation340
of China (No. 51373101), and we thank these bodies for funding. BSV would like to thank the Mexican341
Consejo Nacional de Ciencia y Tecnologia (CONACyT) for the provision of a PhD scholarship. GP thanks342
UCL for the award of an Excellence Fellowship and the EPSRC for financial support in the form of an343
Early Career Fellowship (EP/M014649/1).344
References345
1. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer.346
2003;3:380-7.347
2. Webb CE, Jones JDC. Handbook of laser technology and applications: Laser design and laser348
systems. 1st ed. Baca Raton: CRC Press; 2004.349
3. Pasparakis G, Manouras T, Vamvakaki M, Argitis P. Harnessing photochemical internalization350
with dual degradable nanoparticles for combinatorial photo–chemotherapy. Nat Commun.351
2014;5:1:3623.352
4. Lim E-K, Kim T, Paik S, Haam S, Huh Y-M, Lee K. Nanomaterials for Theranostics: Recent353
Advances and Future Challenges. Chem Rev. 2015;115:327-94.354
5. Lee D-E, Koo H, Sun I-C, Ryu JH, Kim K, Kwon IC. Multifunctional nanoparticles for multimodal355
imaging and theragnosis. Chem Soc Rev. 2012;41:2656-72.356
6. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, et al. Photodynamic therapy357
of cancer: An update. CA Cancer J Clin. 2011;61:250-81.358
7. Huggett MT, Jermyn M, Gillams A, Illing R, Mosse S, Novelli M, et al. Phase I/II study of359
verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer. 2014;110:1698-360
704.361
8. Pietroiusti A, Campagnolo L, Fadeel B. Interactions of Engineered Nanoparticles with Organs362
Protected by Internal Biological Barriers. Small. 2013;9:1557-72.363
9. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric364
therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev. 2012;41:2971-365
3010.366
10. Nomoto T, Fukushima S, Kumagai M, Machitani K, Arnida, Matsumoto Y, et al. Three-layered367
polyplex micelle as a multifunctional nanocarrier platform for light-induced systemic gene transfer.368
Nat Commun. 2014;5:3545.369
11. Nishiyama N, Iriyama A, Jang W-D, Miyata K, Itaka K, Inoue Y, et al. Light-induced gene transfer370
from packaged DNA enveloped in a dendrimeric photosensitizer. Nat Mater. 2005;4:934-41.371
12. Pang X, Wan C, Wang M, Lin Z. Strictly biphasic soft and hard Janus structures: synthesis,372
properties, and applications. Angew Chem Int Ed Engl. 2014;53:5524-38.373
13. Walther A, Muller AHE. Janus particles. Soft Matter. 2008;4:663-8.374
14. Perro A, Reculusa S, Ravaine S, Bourgeat-Lami E, Duguet E. Design and synthesis of Janus375
micro- and nanoparticles. J Mater Chem. 2005;15:3745-60.376
15. Huang Z-M, Zhang YZ, Kotaki M, Ramakrishna S. A review on polymer nanofibers by377
electrospinning and their applications in nanocomposites. Compos Sci Technol. 2003;63:2223-53.378
16. Zhang C-L, Yu S-H. Nanoparticles meet electrospinning: recent advances and future prospects.379
Chem Soc Rev. 2014;43:4423-48.380
17. Gupta P, Wilkes GL. Some investigations on the fiber formation by utilizing a side-by-side381
bicomponent electrospinning approach. Polymer. 2003;44:6353-9.382
18. Chen G, Xu Y, Yu DG, Zhang DF, Chatterton NP, White KN. Structure-tunable Janus fibers383
fabricated using spinnerets with varying port angles. Chemi Commun. 2015;51:4623-6.384
19. Starr JD, Andrew JS. Janus-type bi-phasic functional nanofibers. Chem Commun.385
2013;49:4151-3.386
20. Starr JD, Budi MAK, Andrew JS. Processing-Property Relationships in Electrospun Janus-Type387
Biphasic Ceramic Nanofibers. J Am Ceram Soc. 2015;98:12-9.388
21. Yu D-G, Yang C, Jin M, Williams GR, Zou H, Wang X, et al. Medicated Janus fibers fabricated389
using a Teflon-coated side-by-side spinneret. Colloids Surf B. 2016;138:110-6.390
22. Sun X-T, Yang C-G, Xu Z-R. Controlled production of size-tunable Janus droplets for submicron391
particle synthesis using an electrospray microfluidic chip. RSC Adv. 2016;6:12042-7.392
23. Mou F, Chen C, Guan J, Chen D-R, Jing H. Oppositely charged twin-head electrospray: a general393
strategy for building Janus particles with controlled structures. Nanoscale. 2013;5:2055-64.394
24. Chang C-C, Yang Y-T, Yang J-C, Wu H-D, Tsai T. Absorption and emission spectral shifts of rose395
bengal associated with DMPC liposomes. Dyes Pigments. 2008;79:170-5.396
25. Verma AK, Chanchal A, Maitra A. Co-polymeric hydrophilic nanospheres for drug delivery:397
release kinetics, and cellular uptake. Indian J Exp Biol. 2010;48:1043-52.398
26. Williams GR, Chatterton NP, Nazir T, Yu DG, Zhu LM, Branford-White CJ. Electrospun399
nanofibers in drug delivery: recent developments and perspectives. Therap. Deliv. 2012;3:515-33.400
27. Uppal A, Jain B, Gupta PK, Das K. Photodynamic action of Rose Bengal silica nanoparticle401
complex on breast and oral cancer cell lines. Photochem Photobiol. 2011;87:1146-51.402
28. Lopez FL, Shearman GC, Gaisford S, Williams GR. Amorphous Formulations of Indomethacin403
and Griseofulvin Prepared by Electrospinning. Mol Pharm. 2014;11:4327-38.404
29. Lai W-F, Susha AS, Rogach AL. Multicompartment Microgel Beads for Co-Delivery of Multiple405
Drugs at Individual Release Rates. ACS Appl Mater Interfaces. 2016;8:871-80.406
30. Hwang S, Lahann J. Differentially degradable janus particles for controlled release407
applications. Macromol Rapid Commun. 2012;33:1178-83.408
31. Rahmani S, Villa CH, Dishman AF, Grabowski ME, Pan DC, Durmaz H, et al. Long-circulating409
Janus nanoparticles made by electrohydrodynamic co-jetting for systemic drug delivery applications.410
J Drug Target. 2015;23:750-8.411
32. Wilson BC. Photodynamic therapy for cancer: principles. Can J Gastroenterol. 2002;16:393-6.412
33. Douglas KT. The thymidylate synthesis cycle and anticancer drugs. Med Res Rev. 1987;7:441-413
75.414
34. Mousavi SH, Tavakkol-Afshari J, Brook A, Jafari-Anarkooli I. Direct toxicity of Rose Bengal in415
MCF-7 cell line: Role of apoptosis. Food Chem Toxicol. 2009;47:855-9.416
35. Canti G, Nicolin A, Cubeddu R, Taroni P, Bandieramonte G, Valentini G. Antitumor efficacy of417
the combination of photodynamic therapy and chemotherapy in murine tumors. Cancer Lett.418
1998;125:39-44.419
36. Zhou L, Zhou L, Wei S, Ge X, Zhou J, Jiang H, et al. Combination of chemotherapy and420
photodynamic therapy using graphene oxide as drug delivery system. J Photochem Photobiol B.421
2014;135:7-16.422
37. Nonaka M, Ikeda H, Inokuchi T. Effect of combined photodynamic and chemotherapeutic423
treatment on lymphoma cells in vitro. Cancer Lett. 2002;184:171-8.424
38. Khdair A, Chen D, Patil Y, Ma L, Dou QP, Shekhar MPV, et al. Nanoparticle-mediated425
combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. J Control426
Release. 2010;141:137-44.427
39. Plaetzer K, Krammer B, Berlanda J, Berr F, Kiesslich T. Photophysics and photochemistry of428
photodynamic therapy: fundamental aspects. Laser Med Sci. 2009;24:259-68.429
430
Figures431
432
Figure 1. The chemical structures of PVP, carmofur and rose bengal.433
434
435
Figure 2. SEM images of electrosprayed (a) PVP; (b) PVP-RB; (c) PVP-C; and, (d) PVP-RBC particles,436
together with (e) a fluorescence micrograph of PVP-RBC.437
438
439
440
(a) (b)
Figure 3. Physical form characterization. (a) DSC and (b) XRD data are shown.441
442
443
Figure 4. IR spectra of the raw materials and electrosprayed particles.444
445
446
Figure 5. In vitro drug release from the electrosprayed particles. Data are given from three447
independent experiments as mean ± S.D.448
449
450
(a) (b)
(c) (d)
Figure 6. Cell viability studies with (a) HDF cells; (b) HDF cells exposed to light at 521 nm; (c) A549 cells451
and (d) A549 cells exposed to light at 521 nm. Data are shown from three independent experiments452
as mean ± S.D. *** denotes p < 0.001, and * p < 0.05 with respect to the control (untreated cells).453
454
455
456
Tables457
458
Table 1. Details of the working solutions used for electrospraying. The PVP-RBC particles were459
generated from a side-by-side spinneret using both the rose bengal and carmofur-containing460
solutions.461
ID Functional component(s) Rose bengal conc.
(% w/v)
Carmofur conc.
(% w/v)
Collection
distance (cm)
Voltage
(kV)
PVP - - - 22 15
PVP-RB Rose bengal 0.10 - 22 15
PVP-C Carmofur - 0.86 22 15
PVP-RBC Rose bengal and carmofur 0.10 0.86 20 17
462
463
Table 2. The selectivity of the formulations for cancer cells. The selectivity index is defined as the464
viability of HDF cells divided by the viability of the A549 cells. A value of > 1 indicates that the465
formulation is selective for cancerous cells.466
ID HDF viability (%) A549 viability (%) Selectivity index
PVP 91.1 ± 12.3 91.6 ± 14.8 0.99
PVP-RB 92.3 ± 13.7 72.8 ± 17.6 1.27
PVP-C 1.2 ± 3.5 0.85 ± 5.6 1.41
PVP-RBC 72.4 ± 11.8 0.05 ± 7.5 1450
RB 1.3 ± 4.2 29.4 ± 45.5 0.04
Carmofur 1.6 ± 3.0 2.16 ± 7.8 0.74
467
468
469
